 Hematologic Neoplasms
"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Descriptor ID |
D019337
|
| MeSH Number(s) |
C04.588.448 C15.378.400
|
| Concept/Terms |
Hematologic Neoplasms- Hematologic Neoplasms
- Malignancies, Hematologic
- Malignancy, Hematologic
- Hematological Neoplasms
- Hematological Neoplasm
- Neoplasm, Hematological
- Neoplasms, Hematological
- Neoplasms, Hematologic
- Hematologic Neoplasm
- Neoplasm, Hematologic
- Hematological Malignancies
- Hematological Malignancy
- Malignancies, Hematological
- Malignancy, Hematological
- Hematologic Malignancy
- Hematologic Malignancies
Hematopoietic Neoplasms- Hematopoietic Neoplasms
- Hematopoietic Malignancies
- Hematopoietic Malignancy
- Malignancies, Hematopoietic
- Malignancy, Hematopoietic
- Neoplasms, Hematopoietic
- Hematopoietic Neoplasm
- Neoplasm, Hematopoietic
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".
This graph shows the total number of publications written about "Hematologic Neoplasms" by people in UAMS Profiles by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 2 | 1 | 3 | | 2023 | 7 | 0 | 7 | | 2022 | 4 | 0 | 4 | | 2021 | 8 | 0 | 8 | | 2020 | 3 | 1 | 4 | | 2019 | 2 | 0 | 2 | | 2018 | 2 | 1 | 3 | | 2017 | 3 | 1 | 4 | | 2016 | 2 | 1 | 3 | | 2015 | 3 | 1 | 4 | | 2014 | 2 | 1 | 3 | | 2012 | 2 | 0 | 2 | | 2011 | 1 | 0 | 1 | | 2009 | 1 | 2 | 3 | | 2008 | 1 | 0 | 1 | | 2007 | 2 | 0 | 2 | | 2006 | 2 | 0 | 2 | | 2005 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2003 | 3 | 0 | 3 | | 2002 | 2 | 1 | 3 | | 1997 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles over the past ten years.
-
Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 08 27; 8(16):4320-4329.
-
Al Hadidi S, Heslop HE, Brenner MK, Suzuki M. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
-
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, Waxman AJ, Chong ER, Patel V, Pajarillo R, Kulikovskaya I, Lieberman DB, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Hexner EO, Barta SK, Porter DL, Garfall AL, Schuster SJ, June CH, Ruella M. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024 Apr; 30(4):984-989.
-
Benton LG, Kallen ME, Jacobs JL, McCool IE, Ning Y, Duong VH, Koka R, Singh ZN. Myeloid madness: assessing diagnostic inconsistency between the new WHO and ICC schemes for myelodysplastic/myeloproliferative neoplasms. J Clin Pathol. 2023 Dec 14; 77(1):68-72.
-
Langston RG, Pinckard-Dover H, Guzman G, Wardell CP, Gokden M, Morris TW, Day JD, Rodriguez A. Intracranial hematolymphoid malignancies: A case series with molecular characterization. Clin Neurol Neurosurg. 2023 10; 233:107928.
-
Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.
-
Nath K, Mailankody S, Usmani SZ. The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies. Hematol Oncol Clin North Am. 2023 12; 37(6):1201-1214.
-
Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Curr Oncol Rep. 2023 05; 25(5):479-489.
-
Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2023 02 16; 29(4):711-722.
-
Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience. Transplant Proc. 2023 Jan-Feb; 55(1):214-224.
-
Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, Usmani SZ, Young JW, Zelenetz AD, Noy A, Vardhana SA. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022 06 13; 40(6):590-591.
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
-
Alagpulinsa DA, Toribio MP, Alhallak I, Shmookler Reis RJ. Advances in understanding the molecular basis of clonal hematopoiesis. Trends Mol Med. 2022 05; 28(5):360-377.
-
Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk. 2022 07; 22(7):e495-e497.
-
Lopez-Candales A, Mathur P, Mounsey JP, Veeraputhiran M. Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? Postgrad Med. 2022 Jan; 134(1):7-10.
-
Al Hadidi S, Kamble RT, Carrum G, Heslop HE, Ramos CA. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633.
-
Bonafede M, Anaissie E, Evans K, Itzler R. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis. BMC Health Serv Res. 2021 Oct 20; 21(1):1125.
-
Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, Greenberger LM. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood Cancer Discov. 2021 11; 2(6):562-567.
-
Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, Lai YR, Liu DH, Liu QF, Liu T, Ren HY, Song YP, Sun ZM, Tang XW, Wang JM, Wu DP, Xu LP, Zhang X, Zhou DB, Huang XJ. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021 09 15; 14(1):145.
-
Niu A, Ning B, Socola F, Safah H, Reynolds T, Ibrahim M, Safa F, Alfonso T, Luk A, Mushatt DM, Hu T, Saba NS. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. Leuk Res. 2021 07; 106:106582.
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
-
Ibrahim M, Vegel A, Niu A, Panse K, Chen R, Safah H, Socola F, Luk A, Saba NS. Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. Leuk Res. 2021 02; 101:106514.
-
Taylor J, Donoghue MT, Ho C, Petrova-Drus K, Al-Ahmadie HA, Funt SA, Zhang Y, Aypar U, Rao P, Chavan SS, Haddadin M, Tamari R, Giralt S, Tallman MS, Rampal RK, Baez P, Kappagantula R, Kosuri S, Dogan A, Tickoo SK, Reuter VE, Bosl GJ, Iacobuzio-Donahue CA, Solit DB, Taylor BS, Feldman DR, Abdel-Wahab O. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020 12 01; 130(12):6668-6676.
-
Bernhard ME, Barnes CL, DeFeo BM, Kaste SC, Wang X, Lu Z, Neel MD. Total Hip Arthroplasty in Adolescents and Young Adults for Management of Advanced Corticosteroid-Induced Osteonecrosis Secondary to Treatment for Hematologic Malignancies. J Arthroplasty. 2021 04; 36(4):1352-1360.
-
Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Meyer RE, Canfield MA, Rasmussen SA, Chambers TM, Spector LG, Plon SE, Lupo PJ. Cancer diagnostic profile in children with structural birth defects: An assessment in 15,000 childhood cancer cases. Cancer. 2020 08 01; 126(15):3483-3492.
-
Atrash S, Bano K, Harrison B, Abdallah AO. CAR-T treatment for hematological malignancies. J Investig Med. 2020 06; 68(5):956-964.
-
Kim J, Park J, Lee MO, Park EY, Heo S, Shim JL. Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient-Caregiver Dyadic Analysis. J Palliat Med. 2020 05; 23(5):611-618.
-
Pandey S, Gokden M, Kazemi NJ, Post GR. Hematolymphoid Malignancies Presenting with Spinal Epidural Mass and Spinal Cord Compression: A Case Series with Rare Entities. Ann Clin Lab Sci. 2019 Nov; 49(6):818-828.
-
Onyeama SN, Hanson SJ, Dasgupta M, Baker K, Simpson PM, Punzalan RC. Central Venous Catheter-associated Venous Thromboembolism in Children With Hematologic Malignancy. J Pediatr Hematol Oncol. 2018 11; 40(8):e519-e524.
-
Ahmed J, Karass M, Aujla A, McHale P, Kretschmer P, Mazumder A, Seiter K, Ahmed T, Lim SH, Knoll BM. Late-onset fever and engraftment syndrome following autologous stem cell transplant: Impact on resource utilization. Am J Hematol. 2018 10; 93(10):E336-E338.
-
Pina-Oviedo S, Miranda RN, Medeiros LJ. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. Am J Surg Pathol. 2018 Jan; 42(1):116-129.
-
King J, Pana ZD, Lehrnbecher T, Steinbach WJ, Warris A. Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. J Pediatric Infect Dis Soc. 2017 Sep 01; 6(suppl_1):S12-S21.
-
Morgan GJ, Rasche L. Haematological cancer: Where are we now with the treatment of multiple myeloma? Nat Rev Clin Oncol. 2017 08; 14(8):461-462.
-
Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer. 2017 Sep 15; 123(18):3602-3608.
-
Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. Eur J Med Chem. 2017 Aug 18; 136:393-405.
-
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
-
Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, Miligi L, Beane Freeman LE, de Sanjose S, Bernstein L, Monnereau A, Clavel J, Tricot GJ, Atanackovic D, Cocco P, Orsi L, Dosman JA, McLaughlin JR, Purdue MP, Cozen W, Spinelli JJ, de Roos AJ. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol. 2016 Oct; 175(1):87-101.
-
Liu YL, Yan Y, Webster C, Shao L, Lensing SY, Ni H, Feng W, Colorado N, Pathak R, Xiang Z, Hauer-Jensen M, Li S, Zhou D, Emanuel PD. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood. 2016 Apr 14; 127(15):1912-22.
-
Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA. Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. J Med Chem. 2015 Nov 25; 58(22):8896-906.
-
Mathur P, Paydak H, Thanendrarajan S, van Rhee F. Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):70-5.
-
Nou?r SA, Nucci M, Anaissie E. Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms. Expert Rev Hematol. 2015 Oct; 8(5):647-58.
-
Zhan F, Zangari M, Qiu L. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics. Biomed Res Int. 2015; 2015:384575.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|